Aligos Total Current Assets vs Non Current Assets Total Analysis

ALGS Stock  USD 30.82  3.26  11.83%   
Aligos Therapeutics financial indicator trend analysis is way more than just evaluating Aligos Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aligos Therapeutics is a good investment. Please check the relationship between Aligos Therapeutics Total Current Assets and its Non Current Assets Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aligos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.

Total Current Assets vs Non Current Assets Total

Total Current Assets vs Non Current Assets Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aligos Therapeutics Total Current Assets account and Non Current Assets Total. At this time, the significance of the direction appears to have weak relationship.
The correlation between Aligos Therapeutics' Total Current Assets and Non Current Assets Total is 0.31. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Aligos Therapeutics, assuming nothing else is changed. The correlation between historical values of Aligos Therapeutics' Total Current Assets and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Aligos Therapeutics are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Total Current Assets i.e., Aligos Therapeutics' Total Current Assets and Non Current Assets Total go up and down completely randomly.

Correlation Coefficient

0.31
Relationship DirectionPositive 
Relationship StrengthVery Weak

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.
Most indicators from Aligos Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aligos Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aligos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.At this time, Aligos Therapeutics' Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 3.82 in 2024, whereas Selling General Administrative is likely to drop slightly above 21.4 M in 2024.
 2022 2023 2024 (projected)
Depreciation And Amortization3.7M3.1M3.2M
Interest Income1.6M1.2M1.0M

Aligos Therapeutics fundamental ratios Correlations

-0.320.860.870.910.390.9-0.260.54-0.97-0.60.250.980.39-0.42-0.160.990.76-0.81-0.69-0.320.830.74-0.610.910.5
-0.32-0.46-0.45-0.430.22-0.460.940.290.470.81-0.22-0.430.510.110.89-0.36-0.380.670.531.0-0.31-0.630.55-0.43-0.53
0.86-0.460.980.93-0.050.94-0.550.47-0.91-0.840.270.910.3-0.27-0.240.840.89-0.9-0.88-0.460.970.95-0.810.930.83
0.87-0.450.980.90.040.9-0.520.59-0.9-0.840.470.90.31-0.39-0.180.850.95-0.86-0.84-0.450.970.92-0.760.90.84
0.91-0.430.930.90.111.0-0.440.48-0.93-0.70.210.930.13-0.49-0.180.920.85-0.79-0.92-0.430.870.89-0.881.00.61
0.390.22-0.050.040.110.10.40.44-0.30.240.140.320.21-0.530.180.43-0.050.020.210.22-0.09-0.130.270.11-0.43
0.9-0.460.940.91.00.1-0.490.44-0.93-0.730.180.930.1-0.47-0.230.910.83-0.81-0.93-0.460.870.91-0.891.00.63
-0.260.94-0.55-0.52-0.440.4-0.490.240.450.89-0.16-0.420.440.010.83-0.29-0.420.710.60.94-0.42-0.740.61-0.44-0.7
0.540.290.470.590.480.440.440.24-0.43-0.160.630.460.5-0.670.580.510.66-0.16-0.340.290.550.37-0.230.480.31
-0.970.47-0.91-0.9-0.93-0.3-0.930.45-0.430.73-0.2-1.0-0.280.370.33-0.98-0.760.90.750.47-0.85-0.840.68-0.93-0.59
-0.60.81-0.84-0.84-0.70.24-0.730.89-0.160.73-0.38-0.710.050.140.62-0.59-0.750.90.760.81-0.77-0.910.71-0.7-0.9
0.25-0.220.270.470.210.140.18-0.160.63-0.2-0.380.180.08-0.550.140.230.64-0.15-0.22-0.220.340.29-0.160.210.43
0.98-0.430.910.90.930.320.93-0.420.46-1.0-0.710.180.3-0.38-0.30.980.75-0.89-0.74-0.430.850.84-0.670.930.58
0.390.510.30.310.130.210.10.440.5-0.280.050.080.30.240.430.290.25-0.210.110.510.450.00.220.130.22
-0.420.11-0.27-0.39-0.49-0.53-0.470.01-0.670.370.14-0.55-0.380.24-0.24-0.49-0.490.050.440.11-0.21-0.360.42-0.49-0.01
-0.160.89-0.24-0.18-0.180.18-0.230.830.580.330.620.14-0.30.43-0.24-0.2-0.010.60.230.89-0.09-0.390.25-0.18-0.32
0.99-0.360.840.850.920.430.91-0.290.51-0.98-0.590.230.980.29-0.49-0.20.74-0.8-0.71-0.360.790.75-0.640.920.45
0.76-0.380.890.950.85-0.050.83-0.420.66-0.76-0.750.640.750.25-0.49-0.010.74-0.69-0.83-0.380.910.84-0.770.850.81
-0.810.67-0.9-0.86-0.790.02-0.810.71-0.160.90.9-0.15-0.89-0.210.050.6-0.8-0.690.70.67-0.83-0.870.64-0.79-0.78
-0.690.53-0.88-0.84-0.920.21-0.930.6-0.340.750.76-0.22-0.740.110.440.23-0.71-0.830.70.53-0.81-0.920.99-0.92-0.7
-0.321.0-0.46-0.45-0.430.22-0.460.940.290.470.81-0.22-0.430.510.110.89-0.36-0.380.670.53-0.31-0.630.55-0.43-0.53
0.83-0.310.970.970.87-0.090.87-0.420.55-0.85-0.770.340.850.45-0.21-0.090.790.91-0.83-0.81-0.310.87-0.730.870.85
0.74-0.630.950.920.89-0.130.91-0.740.37-0.84-0.910.290.840.0-0.36-0.390.750.84-0.87-0.92-0.630.87-0.870.890.84
-0.610.55-0.81-0.76-0.880.27-0.890.61-0.230.680.71-0.16-0.670.220.420.25-0.64-0.770.640.990.55-0.73-0.87-0.88-0.64
0.91-0.430.930.91.00.111.0-0.440.48-0.93-0.70.210.930.13-0.49-0.180.920.85-0.79-0.92-0.430.870.89-0.880.61
0.5-0.530.830.840.61-0.430.63-0.70.31-0.59-0.90.430.580.22-0.01-0.320.450.81-0.78-0.7-0.530.850.84-0.640.61
Click cells to compare fundamentals

Aligos Therapeutics Account Relationship Matchups

Aligos Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets146.5M265.3M235.4M146.7M151.5M193.1M
Short Long Term Debt Total14.3M13.0M14.5M12.6M11.1M10.6M
Other Current Liab753K14.1M22.5M12.9M13.6M11.7M
Total Current Liabilities13.8M30.3M39.0M33.1M23.9M27.1M
Total Stockholder Equity(64.9M)220.0M184.7M103.9M92.1M95.7M
Other Liab3.6M4.5M133K233K209.7K199.2K
Net Tangible Assets(64.9M)220.0M184.7M103.9M119.5M94.6M
Property Plant And Equipment Net16.1M14.9M15.0M12.5M9.8M11.1M
Current Deferred Revenue6.8M7.9M7.6M9.2M1.3M1.2M
Net Debt(55.2M)(207.4M)(172.4M)(68.8M)(124.6M)(130.8M)
Retained Earnings(66.2M)(174.7M)(303.1M)(399.1M)(486.8M)(462.5M)
Accounts Payable3.8M3.3M3.0M4.7M2.5M3.7M
Cash69.6M220.4M186.8M81.3M135.7M131.6M
Non Current Assets Total26.3M15.3M30.9M13.1M10.4M14.9M
Non Currrent Assets Other188K(3.3M)866K(2.5M)625K656.3K
Other Assets188K7.3K866K634K(2.4M)(2.3M)
Cash And Short Term Investments117.7M243.5M190.7M125.8M135.7M165.8M
Common Stock Shares Outstanding21.9M34.2M39.9M42.7M24.9M33.9M
Short Term Investments48.1M23.1M3.9M44.5M(70K)(66.5K)
Liabilities And Stockholders Equity146.5M265.3M235.4M146.7M151.5M193.1M
Non Current Liabilities Total197.6M15.0M11.7M9.7M35.5M51.1M
Capital Lease Obligations14.3M13.0M14.5M12.6M11.1M10.6M
Other Current Assets2.0M6.5M13.7M7.7M5.4M6.7M
Other Stockholder Equity(180.7M)395.0M487.3M502.6M578.3M308.4M
Total Liab211.4M45.3M50.6M42.8M59.4M70.8M
Net Invested Capital(64.9M)220.0M184.7M103.9M92.1M95.7M
Property Plant And Equipment Gross16.1M14.9M22.2M22.1M20.6M20.4M
Total Current Assets120.2M250.0M204.4M133.5M141.1M172.6M
Accumulated Other Comprehensive Income(115K)(188K)452K401K545K572.3K
Net Working Capital106.4M219.7M165.5M100.4M117.2M145.6M
Short Term Debt2.5M5.0M5.8M6.3M6.5M5.0M
Property Plant Equipment16.1M14.9M15.0M4.8M4.3M4.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aligos Stock Analysis

When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.